The Economic TimesIndustry
| |

Industry

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

Image for FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta plaques in the brains of Alzheimer's patients.


India’s youngest airline Akasa Air seeks funds as Iran war drives up costs

Akasa Air is raising funds through equity and debt to navigate industry challenges. The airline seeks eight billion rupees from investors and two point five billion rupees in loans. Existing owners will contribute five billion rupees to the equity portion. Despite headwinds, Akasa Air has expanded its operations locally. The company plans further capacity increases in the coming year.

Auto News

Banking/Finance News

Cons. Products News

Energy News

Renewables News

Ind'l Goods/Svs News

Healthcare/Biotech News

Services News

Media/Entertainment News

Transportation News

Telecom